DNLI
Denali Therapeutics Inc
NASDAQ: DNLI · HEALTHCARE · BIOTECHNOLOGY
$18.60
-7.28% today
Updated 2026-04-29
Market cap
$2.95B
P/E ratio
—
P/S ratio
3,643.65x
EPS (TTM)
$-2.97
Dividend yield
—
52W range
$13 – $24
Volume
1.7M
Denali Therapeutics Inc (DNLI) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-45.70%
ROA
-27.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2015 | $0.00 | $-16.79M | — | — | — |
| 2016 | $0.00 | $-86.65M | — | — | — |
| 2017 | $0.00 | $-88.19M | — | — | — |
| 2018 | $129.16M | $-36.24M | 100.00% | -35.90% | -28.06% |
| 2019 | $26.68M | $-197.61M | 100.00% | -799.10% | -740.74% |
| 2020 | $335.66M | $71.14M | 100.00% | 18.69% | 21.19% |
| 2021 | $48.66M | $-290.58M | 100.00% | -607.78% | -597.15% |
| 2022 | $108.46M | $-325.99M | 100.00% | -314.16% | -300.56% |
| 2023 | $330.53M | $-145.22M | 100.00% | -59.51% | -43.94% |
| 2024 | $0.00 | $-422.77M | — | — | — |
| 2025 | $0.00 | $-512.54M | — | — | — |